---
title: "Moderna CEO: Anti-vaccine sentiment in the U.S. is rising, no intention to invest in new clinical trials"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273401119.md"
description: "Moderna CEO Stephane Bancel stated that due to the rising anti-vaccine sentiment in the United States, the company has no intention of investing in new late-stage vaccine clinical trials. He pointed out that if they cannot enter the U.S. market, the investment will be difficult to yield returns. At the same time, regulatory delays and a lack of support from health officials have significantly reduced the potential market size. After taking office, U.S. Health Secretary Xavier Becerra tightened COVID-19 vaccination eligibility and questioned the vaccination arrangements and safety"
datetime: "2026-01-22T16:00:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273401119.md)
  - [en](https://longbridge.com/en/news/273401119.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273401119.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273401119.md) | [English](https://longbridge.com/en/news/273401119.md)


# Moderna CEO: Anti-vaccine sentiment in the U.S. is rising, no intention to invest in new clinical trials

Moderna (MRNA.US) CEO Stephane Bancel stated that due to the increasing opposition from U.S. officials regarding vaccines, the company has no plans to invest in new late-stage vaccine clinical trials.

He pointed out that if they cannot enter the U.S. market, the investment will be difficult to recoup. At the same time, regulatory delays and the lack of support from U.S. health officials are significantly shrinking the potential market size.

After taking office, U.S. Health Secretary Robert F. Kennedy Jr. tightened the eligibility for COVID-19 vaccinations and questioned the vaccination arrangements and safety

### 相關股票

- [Marinus Pharma (MRNS.US)](https://longbridge.com/zh-HK/quote/MRNS.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Moderna (MRNA.US)](https://longbridge.com/zh-HK/quote/MRNA.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)

## 相關資訊與研究

- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-HK/news/281346305.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/zh-HK/news/281517197.md)
- [Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat](https://longbridge.com/zh-HK/news/281233412.md)
- [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/zh-HK/news/281522861.md)
- [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/zh-HK/news/281186075.md)